Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 12, 2019. The report serves as a notification of the vesting of conditional share awards and the subsequent sale or withholding of shares to meet tax liabilities. These transactions relate to awards granted in 2016 under the GlaxoSmithKline Share Value Plan (SVP) to Persons Discharging Managerial Responsibility (PDMRs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details specific equity transactions for individual executives.
| Executive | Position | Instrument | Transaction Type | Volume | Price |
|---|---|---|---|---|---|
| Mr J Ford | SVP & General Counsel | ADSs | Vesting | 6,320 | n/a |
| Mr J Ford | SVP & General Counsel | ADSs | Sale (Tax) | 3,113 | $40.2654 |
| Mr B McNamara | CEO, GSK Consumer Healthcare | ADSs | Vesting | 11,212 | n/a |
| Mr B McNamara | CEO, GSK Consumer Healthcare | ADSs | Sale (Tax) | 5,522 | $40.2654 |
| Mr R Simard | President, Pharma Supply Chain | Ordinary Shares | Vesting | 11,060 | n/a |
| Mr R Simard | President, Pharma Supply Chain | Ordinary Shares | Sale (Tax) | 5,199 | £15.5380 |
| Mrs V A Whyte | Company Secretary | Ordinary Shares | Vesting | 11,060 | n/a |
| Mrs V A Whyte | Company Secretary | Ordinary Shares | Sale (Tax) | 5,199 | £15.5380 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents routine equity compensation events where the restricted period for 2016 awards ended on February 11, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transactions were executed on the New York Stock Exchange (XNYS) for ADSs and the London Stock Exchange (XLON) for Ordinary Shares.
Investor Verification Checklist
- Verify the total number of shares vested and sold by PDMRs to assess insider sentiment.
- Confirm the transaction dates (February 11, 2019) align with the vesting schedule of the 2016 Share Value Plan.
- Note that the filing does not provide company-wide financial performance data; refer to Form 20-F for consolidated results.
- Check the specific exchange listings (XNYS vs. XLON) for the respective instruments traded.